Short Interest in Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) Expands By 21.0%

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) was the recipient of a significant increase in short interest during the month of February. As of February 13th, there was short interest totaling 2,538,952 shares, an increase of 21.0% from the January 29th total of 2,098,448 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average trading volume of 1,518,433 shares, the days-to-cover ratio is presently 1.7 days. Based on an average trading volume of 1,518,433 shares, the days-to-cover ratio is presently 1.7 days. Approximately 0.3% of the shares of the company are short sold.

Elite Pharmaceuticals Stock Up 1.5%

Elite Pharmaceuticals stock opened at $0.39 on Thursday. The firm has a market capitalization of $420.25 million, a PE ratio of 13.01 and a beta of 0.35. The company’s 50-day moving average is $0.44 and its 200-day moving average is $0.54. Elite Pharmaceuticals has a fifty-two week low of $0.27 and a fifty-two week high of $0.82. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.34 and a quick ratio of 5.44.

Elite Pharmaceuticals (OTCMKTS:ELTP) last issued its earnings results on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 EPS for the quarter. Elite Pharmaceuticals had a return on equity of 47.93% and a net margin of 30.98%.The company had revenue of $31.59 million during the quarter.

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.